Interstitial Lung Disease
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1.Aged = 18 years, regardless of gender. 2.Understand the study procedures and methods, participate voluntarily, and sign the written informed consent form. 3.Patients with suspected ILD based on HRCT or thin-section CT requiring hospitalization for definitive diagnosis, or patients with a confirmed diagnosis of IPF or CTD-ILD. 4.No contraindications to bronchoscopy, and assessed as able to tolerate the procedure based on cardiopulmonary function.
Exclusion criteria
Exclusion criteria: 1.History of any significant medical condition which, in the opinion of the investigator, may adversely affect participation. 2.Female subjects who are pregnant or lactating. 3.Hepatitis B surface antigen positive or hepatitis B core antibody positive with HBV DNA =2000 IU/mL; hepatitis C antibody positive with HCV RNA =1000 IU/mL; human immunodeficiency virus antibody positive or a history of acquired immunodeficiency syndrome. 4.Patients with active respiratory tract infection, AECOPD, asthma, or other acute or uncontrolled cardiopulmonary diseases. 5.Presence of any other contraindications to bronchoscopy. 6.Alanine aminotransferase (ALT), aspartate aminotransferase (AST), or ?-glutamyl transferase (GGT) exceeding the Upper Limit of Normal (ULN), or total bilirubin exceeding the ULN at the screening/baseline visit. 7.Refusal to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Organoid Establishment Success Rate;Biological Differences Among ILD Subtype Organoids; | — |
Secondary
| Measure | Time frame |
|---|---|
| Identification of Disease-Associated Biomarkers;Scale of ILD Organoid Biobank Establishment;Accuracy of Drug Response Prediction; | — |
Countries
China
Contacts
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine